Outcomes and Safety

Risks & contraindications

Other

Highlighted claims

• Outcome measures assess quality of life, functioning, disability and impairment, physical symptoms, illness views and healthcare utilisation. — Feasibility of an adjunctive INtervention for Debilitating symptom complexes attributed to ticks (FIND): study protocol for a randomised, waitlist-controlled feasibility trial
• Therapy participants have adverse events reviewed during each treatment session, while waitlist controls are contacted at Week 10 and Week 20. — Feasibility of an adjunctive INtervention for Debilitating symptom complexes attributed to ticks (FIND): study protocol for a randomised, waitlist-controlled feasibility trial
• Questionnaires are administered through REDCap at baseline, Week 10, Week 20 and Week 32 regardless of therapy completion. — Feasibility of an adjunctive INtervention for Debilitating symptom complexes attributed to ticks (FIND): study protocol for a randomised, waitlist-controlled feasibility trial
• Participants who receive therapy complete treatment satisfaction and negative effects questionnaires 20 weeks after starting therapy. — Feasibility of an adjunctive INtervention for Debilitating symptom complexes attributed to ticks (FIND): study protocol for a randomised, waitlist-controlled feasibility trial
• Adverse events may include worsening prior symptoms, recurrence of previous symptoms, diagnosis of a new medical condition, new symptoms or injuries. — Feasibility of an adjunctive INtervention for Debilitating symptom complexes attributed to ticks (FIND): study protocol for a randomised, waitlist-controlled feasibility trial